With ground breaking cystic fibrosis treatment data, Vertex (Nasdaq: VRTX) shares surged 40% in a single day last week. Kalydeco is already approved to treat are rare mutation occurring in 5% of cystic fibrosis suffers, but by combining it with experimental drug VX-809, Vertex is potentially bringing its treatment to nearly half of the CF population. Vertex's drugs special is that they treat the underlying cause of the disease and not just attempt to mitigate symptoms.

In this episode of Where The Money Is, Motley Fool health care analysts David Williamson and Michael Douglass give investors the background of Vertex, explain the sales potential of the CF treatment, discuss some concerns with the data, and whether it is to late to jump on the stock's bandwagon. 


David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.